Knowledge spreads at different paces. A July 2019 article from Clyde & Co. notes a January 2019 medical review article on prostate cancer and links to asbestos. Interestingly, the Clyde & Co. article mentions epidemiology but says nothing about genomics or plausible mechanisms of action.

It’s great to see lawyers writing about scientific article. That said, in my view, it’s important to go beyond epidemiology by also thinking about genomics and mechanisms of action as related to asbestos and as related to prostate cancer. Those other factors can make epidemiology seem more or less logical. That’s why PhD colleagues and I created ToxicoGenomica.